Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update
By S. J. An, T. J. Kim, B. Yoon. Journal of Stroke, 2017
888 citations recorded by the source corpus.
Intracerebral hemorrhage (ICH) is the second most common subtype of stroke and a critical disease usually leading to severe disability or death. ICH is more common in Asians, advanced age, male sex, and low- and middle-income countries. The case fatality rate of ICH is high (40% at 1 month and 54% at 1 year), and only 12% to 39% of survivors can achieve long-term functional independence. Risk factors of ICH are hypertension, current smoking, excessive alcohol consumption, hypocholesterolemia, and drugs. Old age, male sex, Asian ethnicity, chronic kidney disease, cerebral amyloid angiopathy (CAA), and cerebral microbleeds (CMBs) increase the risk of ICH. Clinical presentation varies according to the size and location of hematoma, and intraventricular extension of hemorrhage. Patients with CAA-related ICH frequently have concomitant cognitive impairment. Anticoagulation related ICH is increasing recently as the elderly population who have atrial fibrillation is increasing. As non-vitamin K antagonist oral anticoagulants (NOACs) are currently replacing warfarin, management of NOAC-associated ICH has become an emerging issue.
Subfields: Epidemiology, Neurology
View Paper: https://www.semanticscholar.org/paper/44876973365e8d4f6c5830d16f0c494e34404ff0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- L. Apostolova
- S. Greenberg
- J. Cummings
- P. Aisen
- S. Hendrix
- G. Rabinovici
- Eli Lilly
- R. Petersen
Citations in the corpus
- Lecanemab: Appropriate Use Recommendations (2023, background): “A macrohemorrhage is more likely to occur when patients with pre-existing microbleeds or CAA-ri/ABRA are given anticoagulants (26, 27).”